A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice AJ Dupuy, LM Rogers, J Kim, K Nannapaneni, TK Starr, P Liu, ... Cancer research 69 (20), 8150-8156, 2009 | 195 | 2009 |
Complement in monoclonal antibody therapy of cancer LM Rogers, S Veeramani, GJ Weiner Immunologic research 59, 203-210, 2014 | 137 | 2014 |
Sox2 and Lef-1 interact with Pitx2 to regulate incisor development and stem cell renewal Z Sun, W Yu, M Sanz Navarro, M Sweat, S Eliason, T Sharp, H Liu, ... Development 143 (22), 4115-4126, 2016 | 64 | 2016 |
Ectopic expression of Zmiz1 induces cutaneous squamous cell malignancies in a mouse model of cancer LM Rogers, JD Riordan, BL Swick, DK Meyerholz, AJ Dupuy Journal of Investigative Dermatology 133 (7), 1863-1869, 2013 | 32 | 2013 |
Adaptive immunity does not strongly suppress spontaneous tumors in a Sleeping Beauty model of cancer LM Rogers, AK Olivier, DK Meyerholz, AJ Dupuy The Journal of Immunology 190 (8), 4393-4399, 2013 | 32 | 2013 |
Sequencing methods and datasets to improve functional interpretation of sleeping beauty mutagenesis screens JD Riordan, LJ Drury, RP Smith, BT Brett, LM Rogers, TE Scheetz, ... BMC genomics 15 (1), 1-15, 2014 | 30 | 2014 |
Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy LM Rogers, SL Mott, BJ Smith, BK Link, D Sahin, GJ Weiner Clinical Cancer Research 23 (4), 954-961, 2017 | 14 | 2017 |
A genetic screen to identify gain-and loss-of-function modifications that enhance T-cell infiltration into tumors LM Rogers, Z Wang, SL Mott, AJ Dupuy, GJ Weiner Cancer immunology research 8 (9), 1206-1214, 2020 | 10 | 2020 |
Keratoacanthoma Pathobiology in Mouse Models KN Gibson-Corley, LM Rogers, A Goeken, AJ Dupuy, DK Meyerholz Diseases 2 (2), 106-119, 2014 | 4 | 2014 |
An alternative ZMIZ1 promoter exhibits higher gene expression in epithelial ovarian cancer that is p53-independent N Nadkarni, L Rogers, M Samuelson, T Neff, D Bender, A Ahmed, ... Gynecologic oncology 127 (1), S15-S16, 2012 | 2 | 2012 |
Dual TCR-Expressing T Cells in Cancer: How Single-Cell Technologies Enable New Investigation EM Muhowski, LM Rogers ImmunoHorizons 7 (5), 299-306, 2023 | 1 | 2023 |
Evaluation of the complexity of the immune response to CMP-001, a TLR9 agonist S Sabree, A Voigt, L Rogers, S Blackwell, C Lemke-Miltner, GJ Weiner Cancer Research 80 (16_Supplement), 6666-6666, 2020 | 1 | 2020 |
Complement factor h related protein 1 (CFHR1) serum level correlates with event-free survival in follicular lymphoma patients treated with rituximab LM Rogers, LS Jacobus, AM Button, BK Link, TM Habermann, TE Witzig, ... Blood 122 (21), 4288, 2013 | 1 | 2013 |
1037 Disruption of Aak1 kinase activity improves T cell trafficking into solid tumors by mediating CXCR3 internalization V Vianzon, R Hanson, L Rogers Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
Rank aggregation of independent genetic screen results highlights new strategies for adoptive cellular transfer therapy of cancer VV Vianzon, RM Hanson, I Garg, GJ Joseph, LM Rogers Frontiers in Immunology 14, 2023 | | 2023 |
Genetic manipulations to improve intratumoral trafficking of adoptively transferred T cells V Vianzon, I Garg, LM Rogers The Journal of Immunology 208 (1_Supplement), 116.11-116.11, 2022 | | 2022 |
511 Tumor immune microenvironment in adult mice asynchronously cross-fostered as pups V Vianzon, I Garg, K Greenfield, K Knoop, L Rogers Journal for ImmunoTherapy of Cancer 8 (Suppl 3), A547-A547, 2020 | | 2020 |
A novel genetic screen to identify genes that enhance T cell trafficking into solid tumors LM Rogers, A Dupuy, G Weiner The Journal of Immunology 204 (1_Supplement), 243.10-243.10, 2020 | | 2020 |
Abstract A51: Rationally improving T cell-mediated cancer immunotherapies using Sleeping Beauty mutagenesis to identify novel therapeutic targets LM Rogers, AJ Dupuy, GJ Weiner Cancer Immunology Research 8 (4_Supplement), A51-A51, 2020 | | 2020 |
Rationally improving T cell-mediated cancer immunotherapies using Sleeping Beauty mutagenesis to identify novel therapeutic targets. LM Rogers, AJ Dupuy, GJ Weiner CANCER IMMUNOLOGY RESEARCH 8 (4), 63-63, 2020 | | 2020 |